Systemically-acting pharmacological interventions for spasticity after stroke

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  McCrea, Jonathan T ^a   Langhorne, P ^b   Pandyan, A D ^b   Pollock, A ^b   Van Wijck, F ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; CANNABIS; CARISOPRODOL; CHLORMEZANONE; CHLORZOXAZONE; DANTROLENE; DIAZEPAM; DIMETOTIAZINE; EPERISONE; GABAPENTIN; IDROCILAMIDE; KETAZOLAM; MEDAZEPAM; MEPHENESIN; MEPROBAMATE; METHOCARBAMOL; NEFOPAM; ORPHENADRINE; QUININE; SPASMOLYTIC AGENT; TETRAZEPAM; TIZANIDINE; TOLPERISONE; ZOXAZOLAMINE;

CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; DROWSINESS; DRUG EFFECT; FLU LIKE SYNDROME; HUMAN; MUSCLE SPASM; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; PAIN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SPASTICITY; STROKE; TREATMENT OUTCOME;

EID: 44949248260     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006874     Document Type: Review

References (15)

1. Barnes 2001a Barnes MP. An overview of the clinical management of spasticity. In: BarnesMP, JohnsonGR editor(s). Upper motor neuron syndrome and spasticity. Clinical management and neurophysiology. Cambridge: Cambridge University Press, 2001.
2. Barnes 2001b Barnes MP, Bhakta B, Moore P, Richardson D, Salisbury C, Thornton H, et al. The management of adults with spasticity using botulinum toxin: a guide to clinical practice. Byfleet, Surrey: Radius Healthcare, 2001.
3. BNF 50 The Joint Formulary Committee. British National Formulary 50. British Medical Association and Royal Pharmaceutical Society of Great Britain, September 2005.
4. Deeks 2001 Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM, Davey SmithG, AltmanDG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
5. Lance 1980 Lance JW. Pathophysiology of spasticity and clinical experience with Baclofen. In: LanceJW, FeldmanRG, YoungRR, KoellaWP editor(s). Spasticity: Disordered motor control. Chicago: Year Book, 1980:185-204.
6. Landau 2005 Landau WM. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology 2005;64(11): 1989-90.
7. Lyons 2007 Lyons BE, Moore AP, Bhakta BB, Bamford JM, Cardwell C, Logan ID. Botulinum toxin for adult spasticity after stroke or non-progressive brain lesion. Cochrane Database of Systematic Reviews 2007, Issue 2.Art. No.: CD002926. DOI: 10.1002/14651858.CD002926.pub2.
8. Pandyan 2005 Pandyan AD, Gregoric M, Barnes MP, Wood D, van Wijck FM, Burridge J, et al.Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disability and Rehabilitation 2005;27:2-6.
9. RCP Stroke 2004 Intercollegiate Stroke Working Party. Royal College of Physicians. National clinical guidelines for stroke. 2nd Edition. London: RCP, 2004.
10. Sommerfield 2004 Sommerfield DK, Eek EU, Svensson AK, Holmqvist LW, Von Arbin MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004;35(1):134- 9.
11. Thompson 1998 Thompson AJ. Spasticity rehabilitation: a rational approach to clinical management. In: SheeanG editor(s). Spasticity Rehabilitation. London: Churchill Communications Europe Ltd, 1998.
12. Ward 2001 Ward AB, Ko Ko C. Pharmacological management of spasticity. In: BarnesMP, JohnsonGR editor(s). Upper motor neuron syndrome and spasticity. Clinical management and neurophysiology. Cambridge: Cambridge University Press, 2001.
13. Watkins 2002 Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clinical Rehabilitation 2002;16:515-22.
14. WHO 2003 World Health Organization. The World Health Report: Shaping the future. Geneva: World Health Organization, 2003.
15. Youman 2003 Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the UK. PharmacoEconomics 2003;21(5):43-50.